Brian Mc Kelligon Akoya Biosciences, Inc. (AKYA) insider trading activity

Brian Mc Kelligon is President and CEO of Akoya Biosciences, Inc.. Currently has a direct ownership of 0 shares of AKYA, which is worth approximately $0. The most recent transaction as insider was on Jul 08, 2025, when has been sold 947,688 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Brian McKelligon Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 08 2025	SELL Other acquisition or disposition	-	947,688 Reduced 100.0%	0 Common Stock
Jul 08 2025	SELL Payment of exercise price or tax liability	-	196,866 Reduced 17.2%	947,688 Common Stock
Jul 08 2025	BUY Other acquisition or disposition	-	724,428 Added 38.76%	1,144,554 Common Stock
Mar 23 2025	SELL Payment of exercise price or tax liability	$12,835 $1.7 p/Share	7,550 Reduced 1.77%	420,126 Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$25,765 $1.63 p/Share	15,807 Reduced 3.56%	427,676 Common Stock
Nov 19 2024	BUY Grant, award, or other acquisition	-	218,750 Added 33.03%	443,483 Common Stock
Jun 11 2024	SELL Open market or private sale	$15,600 $2.08 p/Share	7,500 Reduced 3.23%	224,733 Common Stock
Jun 11 2024	BUY Exercise of conversion of derivative security	$2,250 $0.3 p/Share	7,500 Added 3.13%	232,233 Common Stock
Jun 06 2024	SELL Open market or private sale	$15,074 $2.01 p/Share	7,500 Reduced 3.23%	224,733 Common Stock
Jun 06 2024	BUY Exercise of conversion of derivative security	$2,250 $0.3 p/Share	7,500 Added 3.13%	232,233 Common Stock
Mar 23 2024	SELL Payment of exercise price or tax liability	$34,176 $4.79 p/Share	7,135 Reduced 3.08%	224,733 Common Stock
Mar 20 2024	SELL Open market or private sale	$37,275 $4.97 p/Share	7,500 Reduced 3.13%	231,868 Common Stock
Mar 20 2024	BUY Exercise of conversion of derivative security	$2,250 $0.3 p/Share	7,500 Added 3.04%	239,368 Common Stock
Mar 13 2024	SELL Open market or private sale	$37,050 $4.94 p/Share	7,500 Reduced 3.23%	224,368 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$61,771 $6.03 p/Share	10,244 Reduced 9.01%	103,506 Common Stock
Feb 22 2024	BUY Grant, award, or other acquisition	-	87,500 Added 26.71%	240,063 Common Stock
Dec 19 2023	SELL Open market or private sale	$33,600 $4.48 p/Share	7,500 Reduced 4.69%	152,563 Common Stock
Dec 19 2023	BUY Exercise of conversion of derivative security	$2,250 $0.3 p/Share	7,500 Added 4.48%	160,063 Common Stock
Dec 12 2023	SELL Open market or private sale	$31,875 $4.25 p/Share	7,500 Reduced 4.69%	152,563 Common Stock
Dec 12 2023	BUY Exercise of conversion of derivative security	$2,250 $0.3 p/Share	7,500 Added 4.48%	160,063 Common Stock
Nov 20 2023	SELL Open market or private sale	$32,925 $4.39 p/Share	7,500 Reduced 4.69%	152,563 Common Stock
Nov 20 2023	BUY Exercise of conversion of derivative security	$2,250 $0.3 p/Share	7,500 Added 4.48%	160,063 Common Stock
Jun 06 2023	SELL Open market or private sale	$28,550 $5.71 p/Share	5,000 Reduced 3.17%	152,563 Common Stock
Jun 06 2023	BUY Exercise of conversion of derivative security	$1,500 $0.3 p/Share	5,000 Added 3.08%	157,563 Common Stock
Mar 23 2023	SELL Payment of exercise price or tax liability	$57,190 $7.69 p/Share	7,437 Reduced 4.65%	152,563 Common Stock

Brian Mc Kelligon

President and CEO

Marlborough, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKYA shares.

Notify only if

Value

Insider Trading

Get notified when an Akoya Biosciences, Inc. insider buys or sells AKYA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akoya Biosciences, Inc.

Track Activities on AKYA

Account